Experience

University West

• Sweden
• Education Administration Programs
• 400 - 500 Employee

• Head of Grants and Innovation Office (GIO)

  • Sep 2017 - Present



Pronoxis

• Lund, Sweden

• CEO

  • Jan 2013 - Present

  Lead development of small molecules for treatment of severe form of autoimmune conditions. Lead development of small molecules for treatment of severe form of autoimmune conditions.



iNexius AB

• Trollhättan

• CEO

  • Aug 2014 - Present

  iNexius focus on consultations in the are of entrepreneurship and business development. Our core capacities includes several years experiences as founders and creators of small research companies and evaluators of business proposals and applications for European research funding. iNexius focus on consultations in the are of entrepreneurship and business development. Our core capacities includes several years experiences as founders and creators of small research companies and evaluators of business proposals and applications for European research funding.



Karolinska Institutet

• Sweden
• Higher Education
• 700 & Above Employee

• Associated researcher

  • 2011 - Nov 2020

  Co supervision of students and external R&D collaboration. Co supervision of students and external R&D collaboration.



Sahlgrenska Science Park

• Sweden
• Business Consulting and Services
• 1 - 100 Employee

• Business Coach

  • Jan 2015 - Dec 2017

  Engagement as external business adviser and coach for early startup enterprises connected to Sahlgrenska Science Park (SSP). Engagement as external business adviser and coach for early startup enterprises connected to Sahlgrenska Science Park (SSP).



Redoxis AB

• Research Services
• 1 - 100 Employee

• CEO

  • 2007 - Mar 2016

  Redoxis main competence is preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA), multiple sclerosis (MS) and more rare disorders like the Guillain-Barré Syndrome (GBS). We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and… Show more Redoxis main competence is preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA), multiple sclerosis (MS) and more rare disorders like the Guillain-Barré Syndrome (GBS). We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo in animal models and we can assist in design, performance and interpretation of the results from the experiments. Our model systems are well validated and as a small company offer flexible study design. Show less Redoxis main competence is preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA), multiple sclerosis (MS) and more rare disorders like the Guillain-Barré Syndrome (GBS). We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and… Show more Redoxis main competence is preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA), multiple sclerosis (MS) and more rare disorders like the Guillain-Barré Syndrome (GBS). We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo in animal models and we can assist in design, performance and interpretation of the results from the experiments. Our model systems are well validated and as a small company offer flexible study design. Show less



Biovitrum

• Project manager

  • 2005 - 2007

  Project leader of a small group of researcher for discovery and preclinical research of inflammatory diseases. Project leader of a small group of researcher for discovery and preclinical research of inflammatory diseases.



Arexis AB/ Biovitrum AB

• Project manager

  • 2003 - 2007

  Project leader discovery research of Rheumatoid Arthritis. Project leader discovery research of Rheumatoid Arthritis.



Arexis AB

• Project Leader

  • 2003 - 2005

  Project leader discovery research Rheumatoid Arthritis. Project leader discovery research Rheumatoid Arthritis.



Lund University

• Sweden
• Higher Education
• 700 & Above Employee

• PhD student

  • 1998 - 2003

  Molecular genetics of complex inherited diseases, such as Rheumatoid Arthritis and Multiple Sclerosis. Molecular genetics of complex inherited diseases, such as Rheumatoid Arthritis and Multiple Sclerosis.